Literature DB >> 10662390

Pharmacoeconomics and health policy. Current applications and prospects for the future.

P E Greenberg1, A Arcelus, H G Birnbaum, P Y Cremieux, J LeLorier, P Ouellette, M B Slavin.   

Abstract

The use of pharmacoeconomic tools has grown dramatically in the past decade as provision of healthcare throughout the industrialised world has required increased cost consciousness. However, pharmacoeconomic analysis has not yet been fully exploited as a conceptual underpinning for public or private health policy decisions. Pharmacoeconomics is likely to become an increasingly important basis for health policy decisions as a number of significant dynamics evolve in the marketplace, including: (i) consumers acting on their growing access to information and becoming more actively involved in treatment decisions; (ii) payers, providers and patients deepening their interaction and overcoming their traditional (narrow) focus on either costs or benefits alone; and (iii) manufacturers being challenged by other healthcare constituencies as sponsors of cost-based outcomes studies.

Entities:  

Mesh:

Year:  1999        PMID: 10662390     DOI: 10.2165/00019053-199916050-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  9 in total

1.  The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals.

Authors:  J L Glennie; G W Torrance; J F Baladi; C Berka; E Hubbard; D Menon; N Otten; M Rivière
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

Review 2.  The role of cost-effectiveness analysis in managed-care decisions.

Authors:  H Grabowski
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

3.  How to calculate indirect costs in economic evaluations.

Authors:  B Liljas
Journal:  Pharmacoeconomics       Date:  1998-01       Impact factor: 4.981

4.  Pharmacoeconomics in the new millennium. A pharmaceutical industry perspective.

Authors:  R Thwaites; R J Townsend
Journal:  Pharmacoeconomics       Date:  1998-02       Impact factor: 4.981

Review 5.  Common errors and controversies in pharmacoeconomic analyses.

Authors:  S Byford; S Palmer
Journal:  Pharmacoeconomics       Date:  1998-06       Impact factor: 4.981

Review 6.  The societal value of pharmaceuticals. Balancing industrial and healthcare policy.

Authors:  J Grund
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981

7.  The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilization.

Authors:  W H Crown; R L Obenchain; L Englehart; T Lair; D P Buesching; T Croghan
Journal:  Stat Med       Date:  1998-09-15       Impact factor: 2.373

8.  The impact of cost-effectiveness on public and private policies in health care: an international perspective. Introduction and overview.

Authors:  F A Sloan; H G Grabowski
Journal:  Soc Sci Med       Date:  1997-08       Impact factor: 4.634

9.  Foundations of cost-effectiveness analysis for health and medical practices.

Authors:  M C Weinstein; W B Stason
Journal:  N Engl J Med       Date:  1977-03-31       Impact factor: 91.245

  9 in total
  5 in total

1.  A role for two-stage pharmacoeconomic appraisal? Is there a role for interim approval of a drug for reimbursement based on modelling studies with subsequent full approval using phase III data?

Authors:  Suzanne Hill; Nick Freemantle
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

2.  Pharmacoeconomic analyses using discrete event simulation.

Authors:  J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  A Systematic Review on the Extent and Quality of Pharmacoeconomic Publications in Egypt.

Authors:  Samar Farid; Mahmoud Elmahdawy; Darin Baines
Journal:  Clin Drug Investig       Date:  2019-02       Impact factor: 2.859

Review 4.  Pharmacoeconomic burden of undertreating hypertension.

Authors:  Luca Degli Esposti; Giorgia Valpiani
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

5.  Pharmacoeconomic studies in Nepal: the need of the hour.

Authors:  Mahip Acharya
Journal:  Front Pharmacol       Date:  2014-12-08       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.